$ELDN
Eledon Pharmaceuticals, Inc.

2016 Q2 Form 10-Q Financial Statement

#000119312516584673 Filed on May 10, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2016 Q1 2015 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.680M $3.550M $3.340M
YoY Change 17.57% 29.56% 35.77%
% of Gross Profit
Research & Development $592.0K $7.931M $7.730M
YoY Change -89.89% -24.89% 103.42%
% of Gross Profit
Depreciation & Amortization $60.00K $53.00K $60.00K
YoY Change 500.0% 960.0%
% of Gross Profit
Operating Expenses $932.0K $11.48M $11.07M
YoY Change -89.62% -13.68% 76.84%
Operating Profit -$932.0K -$11.48M -$11.07M
YoY Change -89.62% -13.68% 76.84%
Interest Expense $50.00K $50.00K $60.00K
YoY Change 66.67% 25.0%
% of Operating Profit
Other Income/Expense, Net -$70.00K
YoY Change
Pretax Income -$13.53M -$11.43M -$11.02M
YoY Change 51.0% -13.8% 77.46%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$1.002M -$11.43M -$11.02M
YoY Change -88.81% -13.83% 77.46%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$96.64M -$81.64M -$78.71M
COMMON SHARES
Basic Shares Outstanding 22.63M shares 22.63M shares 22.58M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2016 Q1 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $43.90M $54.30M $64.00M
YoY Change -47.24% -42.36% -39.22%
Cash & Equivalents $12.16M $14.30M $24.02M
Short-Term Investments $31.80M $39.90M $39.90M
Other Short-Term Assets $2.300M $2.700M $3.200M
YoY Change -36.11% 22.73% 39.13%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $46.19M $56.99M $67.17M
YoY Change -46.76% -40.84% -37.52%
LONG-TERM ASSETS
Property, Plant & Equipment $401.0K $453.0K $489.0K
YoY Change 18.29% 520.55% 1381.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $300.0K $300.0K $45.00K
YoY Change 566.67% 566.67% -77.5%
Total Long-Term Assets $671.0K $723.0K $804.0K
YoY Change 2.6% 127.36% 245.06%
TOTAL ASSETS
Total Short-Term Assets $46.19M $56.99M $67.17M
Total Long-Term Assets $671.0K $723.0K $804.0K
Total Assets $46.86M $57.71M $67.97M
YoY Change -46.39% -40.29% -36.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.846M $1.886M $1.208M
YoY Change 8.33% -45.08% 57.91%
Accrued Expenses $5.971M $4.291M $4.954M
YoY Change 102.89% 84.96% 42.44%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.817M $6.177M $6.162M
YoY Change 68.22% 7.35% 45.23%
LONG-TERM LIABILITIES
Long-Term Debt $200.0K $100.0K $100.0K
YoY Change
Other Long-Term Liabilities $126.0K $88.00K
YoY Change
Total Long-Term Liabilities $156.0K $126.0K $88.00K
YoY Change 1100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.817M $6.177M $6.162M
Total Long-Term Liabilities $156.0K $126.0K $88.00K
Total Liabilities $7.973M $6.303M $6.250M
YoY Change 71.09% 9.54% 47.3%
SHAREHOLDERS EQUITY
Retained Earnings -$156.4M -$142.9M -$131.4M
YoY Change 44.05% 43.42% 52.21%
Common Stock $195.3M $194.3M $193.2M
YoY Change 2.06% 882972.73% 1.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $38.88M $51.41M $2.782M
YoY Change
Total Liabilities & Shareholders Equity $46.86M $57.71M $67.97M
YoY Change -46.39% -40.29% -36.91%

Cashflow Statement

Concept 2016 Q2 2016 Q1 2015 Q4
OPERATING ACTIVITIES
Net Income -$1.002M -$11.43M -$11.02M
YoY Change -88.81% -13.83% 77.46%
Depreciation, Depletion And Amortization $60.00K $53.00K $60.00K
YoY Change 500.0% 960.0%
Cash From Operating Activities -$10.30M -$9.740M -$8.880M
YoY Change -6.45% -12.25% 37.46%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $17.00K -$220.0K
YoY Change -100.0% -62.22%
Acquisitions
YoY Change
Other Investing Activities $8.150M -$100.0K
YoY Change -133.75%
Cash From Investing Activities $8.150M -$20.00K -$320.0K
YoY Change -133.55% -60.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 40.00K 40.00K
YoY Change -100.0% -33.33% -99.36%
NET CHANGE
Cash From Operating Activities -10.30M -9.740M -8.880M
Cash From Investing Activities 8.150M -20.00K -320.0K
Cash From Financing Activities 0.000 40.00K 40.00K
Net Change In Cash -2.150M -9.720M -9.160M
YoY Change -93.87% -12.35% 4261.9%
FREE CASH FLOW
Cash From Operating Activities -$10.30M -$9.740M -$8.880M
Capital Expenditures $0.00 $17.00K -$220.0K
Free Cash Flow -$10.30M -$9.757M -$8.660M
YoY Change -5.24% -12.45% 34.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22634825 shares
CY2016Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22634825 shares
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22634825 shares
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
94162000
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2016Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
839000
CY2016Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
194253000
CY2016Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
79000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1748000
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
21000
CY2016Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
459000
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
51407000
CY2016Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
126000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
420000
CY2016Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
614000
CY2016Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2016Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2016Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1886000
CY2016Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4291000
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-142864000
CY2016Q1 us-gaap Liabilities
Liabilities
6303000
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57710000
CY2016Q1 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
23000
CY2016Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
6177000
CY2016Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5000
CY2016Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
489000
CY2016Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5000
CY2016Q1 us-gaap Assets
Assets
57710000
CY2016Q1 us-gaap Investments And Cash
InvestmentsAndCash
54250000
CY2016Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
453000
CY2016Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
270000
CY2016Q1 us-gaap Assets Current
AssetsCurrent
56987000
CY2016Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
39947000
CY2016Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
39952000
CY2016Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2737000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14303000
CY2016Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
53362000
CY2016Q1 tkai Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3139000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
105256000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22597144 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22597144 shares
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
193194000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
167000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
900000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
61724000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
88000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
699000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2015Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1208000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4954000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-131438000
CY2015Q4 us-gaap Liabilities
Liabilities
6250000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67974000
CY2015Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
23000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6162000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-55000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
51028000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
45000
CY2015Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
55000
CY2015Q4 us-gaap Assets
Assets
67974000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
489000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
270000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
67170000
CY2015Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
39934000
CY2015Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
39989000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3213000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24023000
CY2015Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
58295000
CY2015Q4 tkai Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
3188000
CY2015Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2018-07-31
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2901964 shares
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11104000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2015Q1 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P30D
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22384233 shares
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-13260000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-85000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13300000
CY2015Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
45000
CY2015Q1 us-gaap Allowance For Loan And Lease Losses Adjustments Net
AllowanceForLoanAndLeaseLossesAdjustmentsNet
34000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13260000
CY2015Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
306000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-11094000
CY2015Q1 us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
34000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1158000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
55000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10559000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
13300000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-45000
CY2016Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
174000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
634000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2741000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2669000
CY2015Q1 us-gaap Business Exit Costs1
BusinessExitCosts1
133000
CY2015Q1 us-gaap Depreciation
Depreciation
5000
CY2015Q1 tkai Interest Income And Other Income Expense Net
InterestIncomeAndOtherIncomeExpenseNet
40000
CY2015Q1 tkai Number Of Milestones Achieved
NumberOfMilestonesAchieved
0 Milestone
CY2016Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9740000
CY2016Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016Q1 dei Amendment Flag
AmendmentFlag
false
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3069443 shares
CY2016Q1 dei Document Type
DocumentType
10-Q
CY2016Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001404281
CY2016Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2016Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q1 dei Entity Registrant Name
EntityRegistrantName
TOKAI PHARMACEUTICALS INC
CY2016Q1 dei Document Period End Date
DocumentPeriodEndDate
2016-03-31
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates, assumptions and judgments reflected in these financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#x2019;s estimates.</p> </div>
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11376000
CY2016Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
50000
CY2016Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016Q1 dei Trading Symbol
TradingSymbol
TKAI
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22625009 shares
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-11426000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-521000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11480000
CY2016Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-37000
CY2016Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
50000
CY2016Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
45000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9720000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
11480000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-17000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
37000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7931000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-663000
CY2016Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
38000
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
37000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1022000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3549000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
678000
CY2016Q1 us-gaap Depreciation
Depreciation
53000
CY2016Q1 tkai Earliest Year Open For Tax Examination
EarliestYearOpenForTaxExamination
2012
CY2016Q1 tkai Interest Income And Other Income Expense Net
InterestIncomeAndOtherIncomeExpenseNet
54000
CY2016Q1 tkai Increase Decrease In Deferred Tax Assets
IncreaseDecreaseInDeferredTaxAssets
4000000
CY2016Q1 tkai Number Of Milestones Achieved
NumberOfMilestonesAchieved
0 Milestone

Files In Submission

Name View Source Status
0001193125-16-584673-index-headers.html Edgar Link pending
0001193125-16-584673-index.html Edgar Link pending
0001193125-16-584673.txt Edgar Link pending
0001193125-16-584673-xbrl.zip Edgar Link pending
d183124d10q.htm Edgar Link pending
d183124dex101.htm Edgar Link pending
d183124dex311.htm Edgar Link pending
d183124dex312.htm Edgar Link pending
d183124dex321.htm Edgar Link pending
d183124dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tkai-20160331.xml Edgar Link completed
tkai-20160331.xsd Edgar Link pending
tkai-20160331_cal.xml Edgar Link unprocessable
tkai-20160331_def.xml Edgar Link unprocessable
tkai-20160331_lab.xml Edgar Link unprocessable
tkai-20160331_pre.xml Edgar Link unprocessable